- Earth Science Tech’s ‘conglomerate’ business model has allowed it to leverage its internal tech stack, real estate, as well as ingredient-sourcing and manufacturing capabilities to capture the profit margins at every step that other companies are forced to outsource
- The company is focused on building a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment
- Earth Science Tech now augments its healthcare operations through investments in real estate, asset management activities, and consumer products business
Earth Science Tech (OTCQB: ETST) is a strategic holding company that brings together innovative businesses across the healthcare, pharmacy, technology and telemedicine, real estate, and consumer products spaces. Its primary operating strategy is to continue building a successful vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. It further supports its healthcare operations through investments in real estate, asset management activities, and consumer products.
Through the operation of these autonomous, revenue-generating divisions, Earth Science Tech has created a “conglomerate” business model that sets it apart from other traditional healthcare offerings in that it is heavily insulated from sector-specific risks. Its investment in real estate is also strategic. Through its subsidiary and diversified real estate company, Avenvi, ETST owns a growing portfolio of real estate holdings, some of which are used by Earth Science Tech’s own compounding pharmacies. For its part, Avenvi houses Mister Med’s standalone compounding pharmacy in Texas. (Mister Meds is one of ETST’s compounding pharmacy brands.)
Beyond the operational benefits, its “conglomerate” business model ensures that Earth Science Tech controls its supply chain. In August, for example, the company completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products. Operating out of a facility in Doral, Florida, Zoolzy is expected to provide ETST’s compounding pharmacies with expanded access to new, highly sought-after APIs. Moreover, the acquisition internalizes procurement of these crucial raw materials, ensuring that the pharmacies secure ingredients at competitive wholesale prices that enhance profit margins (https://ibn.fm/2wTyS).
By leveraging the collective competencies of its subsidiaries, including in-house tech stack, proprietary MOC Doctor network, compounding facilities, and owned real estate, ETST is able to capture the profit margins at every step that other companies are forced to outsource. These benefits reflect in its recent Q1 financial results for the three months ended June 30, 2026. The company’s net income rose 57% year-over-year, while net cash provided by operating activities increased 108% (https://ibn.fm/E7zvH).
“Our fiscal first quarter results reflect steady, compounding progress and the inherent operating leverage within our business model,” said Giorgio R. Saumat, CEO and Chairman of the Board, of the Q1 results. “All of our key operating subsidiaries remained profitable this quarter, further strengthening our balance sheet. While we are pleased with the trajectory, we maintain rigorous internal standards and are actively focused on driving even greater operational efficiencies.”
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
